PVH-CORP.
28.3.2022 09:02:06 CEST | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce that applications for the fourth edition of the Tommy Hilfiger Fashion Frontier Challenge are open. The global program echoes Tommy Hilfiger’s sustainability vision to Waste Nothing and Welcome All, amplifying and supporting new voices in the world of social entrepreneurship who are shaping scalable and disruptive innovations to create a more inclusive future of fashion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005210/en/
In line with Tommy Hilfiger’s commitments towards inclusion, diversity, and acknowledging the gap in equity and equal opportunities, individuals from historically underrepresented communities, including Black, Indigenous, People of Color (BIPOC), people with disabilities and women, are strongly encouraged to apply this year. Applications can be submitted by April 29, 2022, through https://platform.younoodle.com/competition/th_fashion_frontier_challenge_2022 .
“The Tommy Hilfiger Fashion Frontier Challenge aims to bring together entrepreneurs from all walks of life, investing knowledge and resources to unlock the unique power of their innovations,” said Tommy Hilfiger. “As an entrepreneur myself, I always wanted to build a global lifestyle brand that is inclusive of everyone — a philosophy that continues to live through this challenge. I truly believe that by coming together we can drive a future of meaningful and long-lasting change.”
The following prizes will be awarded to the winners to support their business idea:
- A total of €200,000 split between two winners
- Additional €15,000 prize for being elected the “Audience’s Favorite Vote”
- A year-long mentorship with Tommy Hilfiger’s internal global experts
- A year-long INSEAD mentorship and course
Tommy Hilfiger is inviting fans of the brand to participate in the first phase of the challenge as Digital Judges. They will help the brand narrow down all applications to the Top 50. Interested applicants are invited to apply until April 20, 2022, through https://platform.younoodle.com/competition/consumer_vote_tommy_hilfiger_fashion_frontier_challenge_2022 .
The top 50 applicants will then be narrowed down to six finalists through an internal procedure. Each finalist will be invited to further develop their business plan with the support of dedicated Tommy Hilfiger and external experts ahead of the final event. With training from an experienced pitch coach, each finalist will then present their concept to a jury panel and internal Tommy Hilfiger associate audience at the global Tommy Hilfiger Fashion Frontier Challenge final event in early 2023.
“At Tommy Hilfiger, we want to work together with communities to drive innovation, inclusivity, and diversity to drive long-lasting change,” said Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe. “As we kick-off for the fourth Tommy Hilfiger Fashion Frontier Challenge , we really look forward to seeing what ideas come to light that will support communities and help shape the future of fashion.”
Since its inception in 2018, the Tommy Hilfiger Fashion Frontier Challenge has awarded €550,000 to support global entrepreneurs bring their innovative ideas to life, so they can make real changes to their communities. The third edition winners include Lalaland, a Netherlands-based platform that uses artificial intelligence to generate customized and inclusive synthetic models of different ethnicities and UZURI K&Y, a Rwandan-based eco-friendly shoe brand that uses recycled car tires from sub-Saharan Africa and employs local youth. Clothes to Good, a South African-based social enterprise that creates micro-business opportunities and jobs for people with disabilities through textile recycling, was awarded the Audience Favorite vote. More information about Tommy Hilfiger’s sustainability journey, which is powered by PVH’s Forward Fashion strategy can be found on https://global.tommy.com/en_int/about-us-corporate-sustainability .
More information about the Tommy Hilfiger Fashion Frontier Challenge , including how to apply, is available here: https://responsibility.pvh.com/tommy/fashion-frontier-challenge/ .
Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger, and @TommyHilfiger.
About Tommy Hilfiger
TOMMY HILFIGER
is one of the world’s most recognized premium lifestyle brands, uplifting and inspiring consumers since 1985. Colliding the classic with the new to light up what's next, the brand boldly mixes prep style and Americana heritage with fresh perspectives drawn from pop culture to design memorable products and collections. Under Mr. Hilfiger’s vision, TOMMY HILFIGER
captures the playful alchemy needed to drive innovative and immersive consumer experiences. At the heart of the brand is the vision to Waste Nothing and Welcome All, an unwavering commitment to sustainability, inclusivity, diversity, and circularity that powers teams to create a better fashion industry.
Global retail sales of TOMMY HILFIGER products were almost $7 billion in 2020. Across the TOMMY HILFIGER and TOMMY JEANS lifestyles, the collections include mens, womens and kids; footwear and accessories; close to body; and a range of license product lines including eyewear, watches and fragrance. Part of PVH Corp., the Tommy Hilfiger Group is powered by more than 16,000 associates worldwide — boasting an extensive distribution network spanning 100 countries and more than 2,000 retail stores, including its largest global flagship store at tommy.com.
About PVH Corp.
PVH is one of the world’s largest and most admired fashion companies, connecting with consumers in over 40 countries. Our global iconic brands include Calvin Klein
and TOMMY HILFIGER
. Our 140-year history is built on the strength of our brands, our team and our commitment to drive fashion forward for good. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005210/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
